Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Living with SMA isn't just about survival, says columnist. There's also the emotional weight of preparing for the next crisis ...

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...